Education Guide · Updated November 2026

Compounded vs Brand-Name GLP-1: What You Need to Know in 2026

Compounded semaglutide is often advertised at a lower cash price than brand-name Wegovy. It is not an FDA-approved generic, and FDA does not review compounded products for safety, effectiveness, or quality before they are sold. Brand self-pay prices have also dropped a lot. Here is what you need to understand before choosing.

The Basics: What Is Compounding?

Compounding is when a licensed pharmacy mixes a medication itself instead of dispensing the manufacturer’s product. It is permitted under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act and has been part of pharmacy practice for decades.

For GLP-1 medications, a compounding pharmacy starts from semaglutide or tirzepatide as a raw ingredient and makes an injectable. The intended active molecule matches Wegovy or Zepbound, but the product is not made by Novo Nordisk or Eli Lilly and has not been reviewed by the FDA.

Price Comparison

Brand-name self-pay prices as of Nov 4, 2026, from the manufacturers’ own pharmacy pages:

Medication	Brand self-pay price per month	Source
Wegovy pen (semaglutide)	$349 for all doses up to 2.4 mg ($199 for the first 2 fills of the two lowest doses for new patients through Dec 31, 2026)	NovoCare Pharmacy
Wegovy pill (oral semaglutide)	$149 for 1.5 mg, $199 for 4 mg, $299 for 9 mg and 25 mg	NovoCare Pharmacy
Zepbound vial or KwikPen (tirzepatide)	$299 for 2.5 mg, $399 for 5 mg, $449 for 7.5 mg to 15 mg if refilled within 45 days	LillyDirect

Compounded prices vary by provider and change often, so we do not quote a single range. Some telehealth sites now advertise compounded semaglutide below $150 a month. With brand self-pay at $299 to $449 for most patients, the gap is far smaller than it was in 2023.

For a full breakdown of pricing options, see our cheapest GLP-1 guide. If you have employer coverage, our insurance coverage guide walks through prior authorization.

The Key Differences

Manufacturing Standards

Brand-name medications are made in FDA-inspected facilities under Current Good Manufacturing Practices (cGMP), and the products were tested in large clinical trials before approval.

Compounded medications vary by pharmacy type:

503B outsourcing facilities register with the FDA, must follow cGMP, and are subject to FDA inspection.
503A pharmacies fill individual prescriptions and are overseen mainly by state boards of pharmacy. Quality practices vary from pharmacy to pharmacy.

Quality Concerns

In a May 2024 statement, Novo Nordisk said its testing of compounded products found up to 24% impurities in one injectable sample and no semaglutide at all in one oral product labeled as 1 mg/mL. That data comes from a company with a financial interest in discrediting compounded competitors, and independent quality data is limited.

The FDA has also warned about dosing errors with compounded injectable semaglutide, including patients measuring in the wrong units and taking several times the intended dose. If you use a compounded product, confirm the dose in milligrams and the syringe markings with your prescriber and pharmacist.

Clinical Evidence

The major trials (SURMOUNT-1, STEP 1, SURMOUNT-5) used brand-name medications. For a detailed look at how Mounjaro compares to Ozempic, see our head-to-head comparison. No large clinical trials have tested compounded semaglutide or tirzepatide. The same active ingredient should act the same way, but formulation, inactive ingredients, and purity can differ, and nobody has measured the result in trials.

The Legal Situation in 2026

Dates below are from the FDA’s policy page for compounders unless noted.

Semaglutide

February 21, 2025: FDA declared the semaglutide shortage resolved
April 2025: Enforcement discretion ended for 503A pharmacies
May 22, 2025: Enforcement discretion ended for 503B facilities
September 2025: FDA sent warning letters to compounders and telehealth companies over compounded GLP-1 marketing claims
February 2026: Novo Nordisk sued Hims & Hers over its compounded oral and injectable semaglutide, after Hims launched and then pulled a compounded semaglutide pill

Tirzepatide

October 2, 2024: FDA declared the tirzepatide shortage resolved, and confirmed that decision on December 19, 2024
March 2025: Enforcement discretion ended for 503A pharmacies after a court denied an injunction, and for 503B facilities on March 19, 2025
May 7, 2025: A federal court in Texas upheld the FDA’s decision to take tirzepatide off the shortage list

What This Means

503B facilities cannot make copies of these drugs from bulk ingredient, because neither semaglutide nor tirzepatide is on the shortage list or the 503B bulks list. 503A pharmacies may not compound copies “regularly or in inordinate amounts,” but can still compound for an individual patient when a prescriber documents a significant difference from the approved product for that patient.

Platforms such as MEDVi and SkyRx still sell compounded GLP-1s. Whether that holds up under FDA enforcement and ongoing litigation is uncertain.

Bottom line: If you start a compounded GLP-1 today, the product may not stay available. Have a backup plan such as brand-name through insurance or a manufacturer self-pay program.

When to Choose Brand-Name

Choose brand-name if:

Your insurance covers GLP-1 medications (coverage and prior authorization rules vary by plan)
You want the exact product tested in clinical trials
You want regulatory certainty
You are concerned about quality and purity
You can afford manufacturer self-pay pricing ($149 to $449 a month for most doses through NovoCare or LillyDirect)

Where to get brand-name: See our reviews of Ro and Calibrate, which focus on brand-name medications. Your primary care doctor can also prescribe them.

When to Choose Compounded

Compounded may make sense if:

You have no insurance coverage and brand self-pay pricing is out of reach
You accept the regulatory uncertainty
Your provider will tell you which pharmacy makes the product and share its testing
You understand that compounded products were not tested in the clinical trials

Where to get compounded: See our reviews of Hims, MEDVi, Eden, and SkyRx. Prices change often, so confirm on each provider’s site.

How to Verify Pharmacy Quality

If you choose compounded, ask these questions:

Is the pharmacy a 503A pharmacy or a 503B outsourcing facility? 503B facilities must follow cGMP and are FDA-inspected.
Do they test potency on every batch? This checks the active ingredient is present at the labeled strength.
If they claim 503B status, are they on the FDA’s list of registered outsourcing facilities?
Has the pharmacy received FDA warning letters? Search the FDA’s warning letter database.
Is the pharmacy PCAB accredited? This is a voluntary quality marker.

Not every telehealth platform will answer these questions directly. That itself tells you something.

Compare all GLP-1 providers

Browse Provider Directory →

The Bottom Line

The gap between compounded and brand-name GLP-1s has narrowed. Manufacturer self-pay prices start at $149 a month for the Wegovy pill and $299 for the lowest Zepbound dose. The legal environment for compounded versions is getting tighter. Quality concerns are hard to verify independently, but they are real.

If you can afford brand-name through insurance or manufacturer self-pay, that is the safer choice in 2026. If cost is the main barrier, talk with your prescriber about the risks of compounded options and how dosing will work. Whichever you choose, be prepared for side effects during titration and track your body composition.

Compare your options in our provider directory. Providers vary by state, so check California or Texas availability if those are your states.

FAQ

Are compounded GLP-1 medications safe?

Compounded GLP-1s are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality. Quality varies by pharmacy, and the FDA has reported dosing errors with compounded semaglutide. If you use one, ask which pharmacy makes it, ask for testing results, and confirm the dose with your prescriber.

Is compounded semaglutide still legal in 2026?

The FDA declared the semaglutide shortage resolved on February 21, 2025, and its grace periods for compounders have ended. 503A pharmacies may still compound semaglutide for an individual patient when a prescriber documents a significant difference from the approved product. Novo Nordisk sued Hims & Hers over compounded semaglutide in February 2026.

Is compounded tirzepatide still available?

Some telehealth platforms still sell it, under tight limits. The FDA resolved the tirzepatide shortage in October 2024, and a federal court upheld that decision on May 7, 2025. 503B facilities cannot make it from bulk ingredient, and 503A pharmacies are limited to patient-specific compounding. Long-term availability is uncertain.

What is the difference between a 503A and 503B pharmacy?

503A pharmacies are traditional compounding pharmacies regulated mainly by state boards. They fill patient-specific prescriptions. 503B outsourcing facilities register with the FDA, follow cGMP standards, are FDA-inspected, and can produce larger batches.

Should I switch from compounded to brand-name?

If your insurance covers brand-name GLP-1s, switching removes the regulatory and quality uncertainty. If you pay cash, compare: the Wegovy pill is $149 to $299 a month through NovoCare, and Zepbound is $299 to $449 a month through LillyDirect for patients who refill on time. Make any switch with your prescriber, since compounded and brand doses are not always measured the same way.

Guides:

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Tools: GLP-1 Cost Estimator · Body Composition Calculator

Compare: All Providers · Best Compounded Semaglutide · B12/Additive Programs · All Guides

What we checked

This AI-assisted public-source desk check reviewed the FDA’s compounding policy and dosing-error pages, NovoCare Pharmacy and LillyDirect self-pay prices, Novo Nordisk’s May 2024 testing statement, and court and news reports on the tirzepatide case and the Hims lawsuit on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.